Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must not be or have been on highly active antiretroviral therapy.~* Participants must have a CD4 count greater than 250 cells/mm3.~* Participants must be at least 18 years of age.~* Participants must be able and willing to participate and give written informed consent.~* Participants must be able and willing to return for the scheduled follow-up visits.~* In addition, in order to be included in the treatment phase of the study, patients must have at least one stool specimen positive for a soil transmitted helminth.~Exclusion Criteria:~* Participants who have received treatment for helminth infection in the past 6 months (by self report or chart review).~* Participants must not be pregnant at the time of treatment (by urine HCG testing).~* Participants who present with other serious co-morbidities such as severe anaemia, malaria or tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Albendazole
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).